Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 75

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 75
---
 and accountability in AI systems. RenCube’s AI platform includes Explainable
AI by design. All data points, calculations and results are traceable, and all calculations are verifiable and reproducible with the same
result.

Differential Diagnosis

Diseases like cancer are very homogenous,
meaning that markers like TP53 or BRCA are expressed with multiple cancers. To address this homogeneity, differential diagnosis distinguishes
between two or more conditions or diseases that share similar signs, symptoms or characteristics. The goal of differential diagnosis is
to consider and evaluate all possible diagnoses for the patient’s symptoms to determine the most likely cause. Differential diagnosis
therefore aims to identify the underlying condition accurately and guide appropriate treatment and management strategies.

Corporate History

We were incorporated under the
laws of the State of Delaware on January 18, 2011, under the name Putnam Hills Corp. and in 2014 we merged with and changed our name to
DanDrit Biotech USA, Inc. In 2018, we acquired Enochian Biopharma and changed our name to Enochian BioSciences Inc. In August 2023, the
Company changed its corporate name to Renovaro Biosciences Inc. On February 13, 2024, the Company changed its corporate name to Renovaro
Inc. On February 13, 2024, Renovaro Inc. acquired Renovaro Cube Intl Ltd and its subsidiaries, in which Renovaro Cube became a wholly-owned
subsidiary of Renovaro Inc.

Going Concern and Management’s Plans

The financial statements included elsewhere herein for the period ended March
31, 2024, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization
of assets and the satisfaction of liabilities during the normal course of business. As of March 31, 2024, we had cash and cash equivalents
of $312,697, an accumulated deficit of $316,723,472 and a working capital deficit of $19,654,098 and total liabilities of $43,683,784.
We have incurred significant losses from continuing operations, have used cash in our continuing operations, and are dependent on additional
financing to fund operations. These conditions raise substantial doubt about our ability to continue as a going concern for one year after
the date the financial statements are issued. The financial statements included elsewhere herein do not include any adjustments to reflect
the possible future effects on the recoverability